α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients Source: Eur Respir J 2007; 29: 240-250 Year: 2007
The role of matrix metalloproteinases in cystic fibrosis lung disease Source: Eur Respir J 2011; 38: 721-727 Year: 2011
Anti-inflammatory cytokines in cystic fibrosis lung disease Source: Eur Respir J 2006; 28: 581-587 Year: 2006
Neutrophilic inflammation predisposes to structural lung disease in cystic fibrosis (CF) via neutrophil elastase activity Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
Inhibition of airway proteases in cystic fibrosis lung disease Source: Eur Respir J 2008; 32: 783-795 Year: 2008
Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease Source: Eur Respir J 2006 Oct 01;28(4):824-831 Year: 2006
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy}, Source: Eur Respir J 2012; 40: 641-648 Year: 2012
Inhaled heparin in cystic fibrosis Source: Eur Respir J 2006; 27: 354-358 Year: 2006
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013
The use of non-invasive inflammatory markers to predict presence, severity and stability of cystic fibrosis lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 327s Year: 2006
Efficacy and tolerability of tetomilast, a new inhibitor of neutrophilic inflammation, in chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006
Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013
Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015
Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016
Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis Source: International Congress 2016 – Connective tissue disorders Year: 2016
Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis Source: Eur Respir J 2002; 19: 294-302 Year: 2002
Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement Source: Eur Respir J 2009; 33: 882-896 Year: 2009
Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis Source: Eur Respir J, 51 (3) 1701910; 10.1183/13993003.01910-2017 Year: 2018
Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition Source: ERJ Open Res, 5 (1) 00252-2018; 10.1183/23120541.00252-2018 Year: 2019
New insights into the pathophysiology of lung disease in cystic fibrosis patients Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=1 Year: 2006